Document is current
Any future updates will be listed below
-
Authors
Hindso, Tine Gadegaard https://orcid.org/0000-0001-5368-511X
Martinussen, Torben https://orcid.org/0000-0002-9760-6791
Bjerrum, Camilla Wium
Keller, Sune Høgild https://orcid.org/0000-0002-8096-6504
Loft, Annika https://orcid.org/0000-0001-5907-3413
Sjøl, Mette Bagger https://orcid.org/0000-0001-6381-8465
Nissen, Kristoffer https://orcid.org/0000-0002-8007-8611
Faber, Carsten https://orcid.org/0000-0002-2517-7270
Donia, Marco https://orcid.org/0000-0003-4966-9752
Svane, Inge Marie https://orcid.org/0000-0002-9451-6037
Ellebaek, Eva https://orcid.org/0000-0001-6748-9232
Heegaard, Steffen
Kiilgaard, Jens Folke https://orcid.org/0000-0003-1054-1460
Madsen, Karine
-
Funding
Funding for this research was provided by:
Øjenforeningen (NA)
Synoptik-Fonden (NA)
Righospitalets Forskningslegat
Kræftens Bekæmpelse (R302-A17321)
- License Information
-
More Information
Article History
Received: 27 November 2024
Accepted: 29 January 2025
First Online: 3 February 2025
Declarations
:
: J.F.K. is a consultant at Aura Biosciences. I.M.S. owns stocks in IO Biotech and has received honoraria from IO Biotech, MSD, Pierre Fabre, Novartis, and TILT Biotherapeutics for consultancies, honoraria for presentations and lectures from BMS, MSD, Novartis, Pierre Fabre, Sanofi Aventis, Novo Nordisk, and Takeda, and travel/conference expenses from MSD. E.E. has received honoraria for consultancies and lectures from Pierre Fabre, BMS, and Novartis, and travel/conference expenses from MSD and Pierre Fabre. M.D. has received proprietary data access from Genentech and Bristol-Myers Squibb and is an advisor at Achilles Therapeutics. The other authors declare no conflicts of interest.
